Key result
Asymmetric dimethylarginine (ADMA) is associated with the progression of chronic kidney disease, potentially through mechanisms involving glomerular filtration barrier compromise and renal fibrosis.
ADMA is highlighted as a significant marker for endothelial dysfunction and a potential mechanistic contributor to the progression of chronic kidney disease.
Answers are grounded in this paper and cite their sources.
ADMA may flag CKD progression risk; hypothesis-generating and should not yet change practice or prompt targeted therapy.
Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid found in tissues and cells that circulates in plasma and is excreted in urine. It inhibits nitric oxide synthases (NOs) and produces considerable cardiovascular biological effects. Several studies have suggested that plasma concentrations of ADMA provide a marker of risk for endothelial dysfunction and cardiovascular disease. In animal and in population studies ADMA has been associated with progression of CKD. Several mechanisms may be involved in this association, such as compromise of the integrity of the glomerular filtration barrier and development of renal fibrosis. This review summarizes the existing literature on the biology and physiology of ADMA focusing on its role in the progression of renal disease.
No takes yet. Share an insight, caveat, or question.
Raptis et al. (2012) conducted a review in Renal disease. Asymmetric dimethylarginine (ADMA) was evaluated on Progression of renal disease. Asymmetric dimethylarginine (ADMA) is associated with the progression of chronic kidney disease, potentially through mechanisms involving glomerular filtration barrier compromise and renal fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: